Key statistics
As of last trade Innoviva Inc (INVA:NSQ) traded at 22.86, -9.11% below its 52-week high of 25.15, set on Feb 26, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.36 |
|---|---|
| High | 22.93 |
| Low | 22.10 |
| Bid | 22.83 |
| Offer | 22.88 |
| Previous close | 22.30 |
| Average volume | 851.13k |
|---|---|
| Shares outstanding | 74.07m |
| Free float | 73.33m |
| P/E (TTM) | 7.20 |
| Market cap | 1.65bn USD |
| EPS (TTM) | 3.10 USD |
Data delayed at least 15 minutes, as of Mar 04 2026 19:29 GMT.
More ▼
- Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
- Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
- U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
- Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
